AI Article Synopsis
- Current vaccines for pulmonary infections caused by Pseudomonas aeruginosa (PA) are limited due to the pathogen's varied genome.
- The study identified two PA antigens, PcrV and AmpC, that effectively stimulate Th17 responses, which are crucial for non-antibody-based protection.
- An innovative vaccine, PVAC, combining specific Th17-stimulating epitopes, was developed and shown to provide broad protective immunity against PA through intranasal immunization.
Article Abstract
Pulmonary infection caused by (PA) has created an urgent need for an efficient vaccine, but the protection induced by current candidates is limited, partially because of the high variability of the PA genome. Antigens targeting pulmonary Th17 responses are able to provide antibody-independent and broad-spectrum protection; however, little information about Th17-stimulating antigens in PA is available. Herein, we identified two novel PA antigens that effectively induce Th17-dependent protection, namely, PcrV (PA1706) and AmpC (PA4110). Compared to intramuscular immunization, intranasal immunization enhanced the protection of rePcrV due to activation of a Th17 response. The Th17-stimulating epitopes of PcrV and AmpC were identified, and the recombinant protein PVAC was designed and generated by combining these Th17-stimulating epitopes. PVAC was successfully produced in soluble form and elicited broad protective immunity against PA. Our results provide an alternative strategy for the development of Th17-based vaccines against PA and other pathogens.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859429 | PMC |
| http://dx.doi.org/10.3389/fimmu.2020.601601 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a Chimeric Vaccine Against Based on the Th17-Stimulating Epitopes of PcrV and AmpC.
Front Immunol
June 2021
National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.
Article Synopsis
- Current vaccines for pulmonary infections caused by Pseudomonas aeruginosa (PA) are limited due to the pathogen's varied genome.
- The study identified two PA antigens, PcrV and AmpC, that effectively stimulate Th17 responses, which are crucial for non-antibody-based protection.
- An innovative vaccine, PVAC, combining specific Th17-stimulating epitopes, was developed and shown to provide broad protective immunity against PA through intranasal immunization.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!